610791-34-9

Basic information

• Product Name: 2-amino-5-methyl-3-phenylhexane
• CAS NO: 610791-34-9
• Molecular Weight: 191.316
• Mol File: 610791-34-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-amino-5-methyl-3-phenylhexane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-5-methyl-3-phenylhexane(610791-34-9)
• EPA Substance Registry System: 2-amino-5-methyl-3-phenylhexane(610791-34-9)

Safety Data

• Hazardous Substances Data: 610791-34-9(Hazardous Substances Data)

Upstream product

• 14320-58-2 4-methyl-2-phenyl-n-pentanoic acid 
• 103392-12-7 5-Methyl-3-phenyl-2-hexanone 
• 605680-32-8 N-methoxy-N-methyl-4-methyl-2-phenylpentanamide 
• 605680-33-9 5-methyl-3-phenyl-2-hexanol 
• 103-82-2 phenylacetic acid 
• 605680-34-0 2-azido-5-methyl-3-phenylhexane 

Relevant articles and documents

SUBSTITUTED SULFONAMIDES

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED ARYL AMIDES

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.